Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
Titel:
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
Auteur:
Mamounas, E.P. Untch, M. Mano, M.S. Huang, C.-S. Geyer Jr, C.E. von Minckwitz, G. Wolmark, N. Pivot, X. Kuemmel, S. DiGiovanna, M.P. Kaufman, B. Kunz, G. Conlin, A.K. Alcedo, J.C. Kuehn, T. Wapnir, I. Fontana, A. Hackmann, J. Polikoff, J. Saghatchian, M. Brufsky, A. Yang, Y. Zimovjanova, M. Boulet, T. Liu, H. Tesarowski, D. Lam, L.H. Song, C. Smitt, M. Loibl, S.